Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Methods for treatment of cancer with therapeutic combinations comprising PEG-IL-10
US10568968B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10568968-B2 |
| Application number | US-201715803516-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 3, 2017 |
| Priority date | Sep 28, 2006 |
| Publication date | Feb 25, 2020 |
| Grant date | Feb 25, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting or reducing growth of a tumor or cancer in a subject in need thereof, the method comprising: administering to the subject an effective amount of a pegylated interleukin-10 (PEG-IL-10) in combination with temozolomide, aemcitabine, doxorubicin, or interferon-alpha, wherein the PEG-IL-10 is human PEG-IL-10, wherein the PEG component of the PEG-IL-10 is about 5 to 20 kDa and is covalently attached to a single amino acid residue of the IL-10 protein, wherein the PEG-IL-10 is dosed at 0.1 to 20 μg per kg of body weight per day, and wherein the tumor or cancer is breast cancer, melanoma, colon cancer, or lung cancer, and wherein temozolomide is dosed at 5 mg to 250 mg, aemcitabine is dosed at 200 mg to 1 g, doxorubicin is dosed at 1 mg/m 2 to 50 mg/m 2 , or interferon-alpha is dosed at 1 μg/kg to 300 μg/kg. 2. The method of claim 1 , wherein the cancer is lung cancer. 3. The method of claim 1 , wherein the PEG-IL-10 further comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for metastasis · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10568968B2 cover?
- Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.
- Who is the assignee on this patent?
- Merck Sharp & Dohme
- What technology area does this patent fall under?
- Primary CPC classification A61K47/60. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).